TG Therapeutics (TGTX) traded higher Monday as the market looked ahead to the company’s first-quarter 2026 financial results and business update, scheduled for Wednesday, May 6, 2026 at 8:30 a.m. ET. With the stock already in a strong uptrend tied to BRIUMVI’s commercial ramp, modest incremental buying and positioning ahead of the catalyst appeared to be driving the move rather than a new same-day headline.

Investors are primarily focused on BRIUMVI execution in relapsing multiple sclerosis, with the company previously laying out a Q1 2026 target for BRIUMVI U.S. net product revenue of approximately $185–$190 million and full-year 2026 target total global revenue of about $875–$900 million (including $825–$850 million in U.S. net product revenue). The May 6 call is the next major checkpoint for prescription momentum, gross-to-net dynamics, and operating expense cadence as TG funds clinical programs and commercial expansion.

Beyond quarterly numbers, TG has highlighted multiple upcoming development milestones that investors track closely for longer-duration upside. Those include topline data timing for the ENHANCE trial evaluating a consolidated Day 1 and Day 15 IV BRIUMVI dosing regimen (mid-year 2026) and topline data expectations for the pivotal subcutaneous BRIUMVI program (year-end 2026 or Q1 2027), alongside additional data planned for the azer-cel program in progressive MS in the second half of 2026.

The key swing factor on May 6 is whether results and commentary reinforce confidence in the 2026 revenue trajectory and the competitive narrative for BRIUMVI within anti-CD20 therapies. Any discussion around demand durability, payer and infusion dynamics, or additional capital deployment (including share repurchases) could amplify the stock’s reaction.